Clinical Trials Browser

Phase 2 × Terminated × Breast Neoplasms, Male × Clear all

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00323063 2023-03-29

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Phase 2 Terminated

49 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00470249 2021-02-01

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT00622466 2020-10-19

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Phase 2 Terminated

20 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01394211 2018-07-26

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00852332 2018-07-24

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Phase 2 Terminated

12 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00376805 2017-12-28

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase 2 Terminated

6 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01868503 2017-06-26

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01151449 2017-04-11

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01729884 2017-04-11

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT00176488 2017-03-23

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Phase 2 Terminated

31 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00824733 2016-01-14

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00132002 2015-03-19

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Phase 2 Terminated

14 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00095888 2013-01-16

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Phase 2 Terminated

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male